Data presented by Eli Lilly & Co. at the American Society of Clinical Oncology annual meeting on the CDK4/CDK6 inhibitor abemaciclib in patients with hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer could be strong enough to support an accelerated approval and position the drug for a faster showdown with Pfizer Inc.’s Ibrance (palbociclib).
Lilly believes abemaciclib has the potential to be a best-in-class drug in a powerful category because of its potent efficacy...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)